Adzenys XR-ODT
Attention Deficit Hyperactivity Disorder (ADHD)
Approved/CommercialMarketed
Key Facts
Indication
Attention Deficit Hyperactivity Disorder (ADHD)
Phase
Approved/Commercial
Status
Marketed
Company
About Aytu BioScience
Aytu BioScience is a commercial-stage biopharmaceutical company with a mission to identify, acquire, and commercialize novel therapeutics for patients with high unmet medical needs. Its strategy centers on building a diversified portfolio of commercial products and late-stage development candidates, primarily in rare pediatric and central nervous system disorders. The company generates revenue from its commercial assets while advancing its pipeline to drive future growth. Aytu's focus on underserved markets aims to create significant value for patients and shareholders.
View full company profileTherapeutic Areas
Other Attention Deficit Hyperactivity Disorder (ADHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BMB-101 | Bright Minds Biosciences | Phase 2 |
| Cotempla XR-ODT | Aytu BioScience | Approved/Commercial |